These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 30339020)

  • 21. Measuring TCR-pMHC Binding In Situ using a FRET-based Microscopy Assay.
    Axmann M; Schütz GJ; Huppa JB
    J Vis Exp; 2015 Oct; (105):e53157. PubMed ID: 26555227
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dissecting TCR-MHC/peptide complex interactions with A2/peptide multimers incorporating tumor antigen peptide variants: crucial role of interaction kinetics on functional outcomes.
    Dutoit V; Guillaume P; Cerottini JC; Romero P; Valmori D
    Eur J Immunol; 2002 Nov; 32(11):3285-93. PubMed ID: 12555674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Force-Regulated In Situ TCR-Peptide-Bound MHC Class II Kinetics Determine Functions of CD4+ T Cells.
    Hong J; Persaud SP; Horvath S; Allen PM; Evavold BD; Zhu C
    J Immunol; 2015 Oct; 195(8):3557-64. PubMed ID: 26336148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Establishment of the reversible peptide-major histocompatibility complex (pMHC) class I Histamer technology: tool for visualization and selection of functionally active antigen-specific CD8(+) T lymphocytes.
    Tischer S; Kaireit T; Figueiredo C; Hiller O; Maecker-Kolhoff B; Geyeregger R; Immenschuh S; Blasczyk R; Eiz-Vesper B
    Int Immunol; 2012 Sep; 24(9):561-72. PubMed ID: 22740564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
    Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
    Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distinct sets of alphabeta TCRs confer similar recognition of tumor antigen NY-ESO-1157-165 by interacting with its central Met/Trp residues.
    Derré L; Bruyninx M; Baumgaertner P; Ferber M; Schmid D; Leimgruber A; Zoete V; Romero P; Michielin O; Speiser DE; Rufer N
    Proc Natl Acad Sci U S A; 2008 Sep; 105(39):15010-5. PubMed ID: 18809922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen.
    Denkberg G; Lev A; Eisenbach L; Benhar I; Reiter Y
    J Immunol; 2003 Sep; 171(5):2197-207. PubMed ID: 12928363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interplay between TCR affinity and necessity of coreceptor ligation: high-affinity peptide-MHC/TCR interaction overcomes lack of CD8 engagement.
    Kerry SE; Buslepp J; Cramer LA; Maile R; Hensley LL; Nielsen AI; Kavathas P; Vilen BJ; Collins EJ; Frelinger JA
    J Immunol; 2003 Nov; 171(9):4493-503. PubMed ID: 14568922
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients.
    Wieckowski S; Baumgaertner P; Corthesy P; Voelter V; Romero P; Speiser DE; Rufer N
    J Immunol; 2009 Oct; 183(8):5397-406. PubMed ID: 19786555
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insights from in situ analysis of TCR-pMHC recognition: response of an interaction network.
    Zhu C; Jiang N; Huang J; Zarnitsyna VI; Evavold BD
    Immunol Rev; 2013 Jan; 251(1):49-64. PubMed ID: 23278740
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen.
    Rodolfo M; Luksch R; Stockert E; Chen YT; Collini P; Ranzani T; Lombardo C; Dalerba P; Rivoltini L; Arienti F; Fossati-Bellani F; Old LJ; Parmiani G; Castelli C
    Cancer Res; 2003 Oct; 63(20):6948-55. PubMed ID: 14583496
    [TBL] [Abstract][Full Text] [Related]  

  • 32. T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells.
    Tan MP; Gerry AB; Brewer JE; Melchiori L; Bridgeman JS; Bennett AD; Pumphrey NJ; Jakobsen BK; Price DA; Ladell K; Sewell AK
    Clin Exp Immunol; 2015 May; 180(2):255-70. PubMed ID: 25496365
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma.
    Rimoldi D; Rubio-Godoy V; Dutoit V; Lienard D; Salvi S; Guillaume P; Speiser D; Stockert E; Spagnoli G; Servis C; Cerottini JC; Lejeune F; Romero P; Valmori D
    J Immunol; 2000 Dec; 165(12):7253-61. PubMed ID: 11120859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early T cell receptor signals globally modulate ligand:receptor affinities during antigen discrimination.
    Pielak RM; O'Donoghue GP; Lin JJ; Alfieri KN; Fay NC; Low-Nam ST; Groves JT
    Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12190-12195. PubMed ID: 29087297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Normalized Synergy Predicts That CD8 Co-Receptor Contribution to T Cell Receptor (TCR) and pMHC Binding Decreases As TCR Affinity Increases in Human Viral-Specific T Cells.
    Williams CM; Schonnesen AA; Zhang SQ; Ma KY; He C; Yamamoto T; Eckhardt SG; Klebanoff CA; Jiang N
    Front Immunol; 2017; 8():894. PubMed ID: 28804489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T-cell receptor affinity in the age of cancer immunotherapy.
    Hoffmann MM; Slansky JE
    Mol Carcinog; 2020 Jul; 59(7):862-870. PubMed ID: 32386086
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Essential Role of the Avidity of T-Cell Receptor in Differentiation of Self-Antigen-reactive CD8+ T Cells.
    Kondo K; Fujiki F; Nakajima H; Yatsukawa E; Morimoto S; Tatsumi N; Nishida S; Nakata J; Oka Y; Tsuboi A; Hosen N; Oji Y; Sugiyama H
    J Immunother; 2016 Apr; 39(3):127-39. PubMed ID: 26938946
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses.
    Jäger E; Nagata Y; Gnjatic S; Wada H; Stockert E; Karbach J; Dunbar PR; Lee SY; Jungbluth A; Jäger D; Arand M; Ritter G; Cerundolo V; Dupont B; Chen YT; Old LJ; Knuth A
    Proc Natl Acad Sci U S A; 2000 Apr; 97(9):4760-5. PubMed ID: 10781081
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulatory T cell depletion enhances tumor specific CD8 T-cell responses, elicited by tumor antigen NY-ESO-1b in hepatocellular carcinoma patients, in vitro.
    Zhang HH; Mei MH; Fei R; Liao WJ; Wang XY; Qin LL; Wang JH; Wei L; Chen HS
    Int J Oncol; 2010 Apr; 36(4):841-8. PubMed ID: 20198327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Estimation of an NY-ESO-1 expressing HCC cell line by NY-ESO-1b specific CD8+T cells in vitro induced by HLA-A2 restricted NY-ESO-1b peptide].
    Qiao H; Qian XP; Zhang HG; Tian C; Chen WF
    Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Dec; 37(6):565-8. PubMed ID: 16378102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.